Biological and Clinical Implications of Gene-Expression Profiling in Diffuse Large B-Cell Lymphoma: A Proposal for a Targeted BLYM-777 Consortium Panel as Part of a Multilayered Analytical Approach

Groot, F.A. de; Groen, R.A.L. de; Berg, A. van den; Jansen, P.M.; Lam, K.H.; Mutsaers, P.G.N.J.; ... ; Vermaat, J.S.P. (2022)

Article / Letter to editor

Simple Summary This review summarizes gene-expression profiling insights into the background and origination of diffuse large B-cell lymphomas (DLBCL). To further unravel the molecular biology of these lymphomas, a consortium panel called BLYM-777 was designed including genes important for subtype classifications, genetic pathways, tumor-microenvironment, immune response and resistance to targeted therapies. This review proposes to combine this transcriptomic method with genomics, proteomics, and patient characteristics to facilitate diagnostic classification, prognostication, and the development of new targeted therapeutic strategies in DLBCL. Gene-expression profiling (GEP) is used to study the molecular biology of lymphomas. Here, advancing insights from GEP studies in diffuse large B-cell lymphoma (DLBCL) lymphomagenesis are discussed. GEP studies elucidated subtypes based on cell-of-origin principles and profoundly changed the biological understanding of DLBCL with clinical relevance. Studies integrating GEP and next-generation DNA sequencing defined different molecular subtypes of DLBCL entities originating at specific anatomical localizations. With the emergence of high-throughput technologies, the tumor microenvironment (TME) has been recognized as a critical component in DLBCL pathogenesis. TME studies have characterized so-called "lymphoma microenvironments" and "ecotypes". Despite gained insights, unexplained chemo-refractoriness in DLBCL remains. To further elucidate the complex biology of DLBCL, we propose a novel targeted GEP consortium panel, called BLYM-777. This knowledge-based biology-driven panel includes probes for 777 genes, covering many aspects regarding B-cell lymphomagenesis (f.e., MYC signature, TME, immune surveillance and resistance to CAR T-cell therapy). Regarding lymphomagenesis, upcoming DLBCL studies need to incorporate genomic and transcriptomic approaches with proteomic methods and correlate these multi-omics data with patient characteristics of well-defined and homogeneous cohorts. This multilayered methodology potentially enhances diagnostic classification of DLBCL subtypes, prognostication, and the development of novel targeted therapeutic strategies.

• gene-expression profiling
• DLBCL
• integration genomics
• localization

• All authors: Groot, F.A. de; Groen, R.A.L. de; Berg, A. van den; Jansen, P.M.; Lam, K.H.; Mutsaers, P.G.N.J.; Noesel, C.J.M. van; Chamuleau, M.E.D.; Stevens, W.B.C.; Placa, J.R.; Mous, R.; Kersten, M.J.; Poel, M.M.W. van der; Tousseyn, T.; Woei-a-Jin, F.J.S.H.; Diepstra, A.; Nijland, M.; Vermaat, J.S.P.
• Date: 2022-04-01
• Journal: Cancers
• Volume: 14
• Issue: 8
• DOI: doi:10.3390/cancers14081857